Archive: Company News
Company News: Agena Bioscience Introduces New Lung and Colon Cancer Panels for Detection of Somatic Mutations from Liquid Biopsies and Solid Tumor Tissues
Agena Bioscience today introduced new targeted research panels for the detection of somatic mutations from lung and colon cancers. The UltraSEEK™ Lung and Colon Panels enable detection of mutations as low as 0.1% minor allele frequency (MAF) from circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). The iPLEX® HS Lung and Colon Panels enable detection of mutations as low as 1% MAF from solid tumor tissue. The new panels are now commercially available worldwide.
Company News: Cebit 2017: Computational Biologists Predict Antibiotic Resistances Using Biotech
Every year, some 25,000 people die in the European Union from antibiotic-resistant, hard to treat bacteria. Although there are diagnostic methods in place to recognize such resistances in advance, these are typically very time-consuming. Researchers from the Center for Bioinformatics at Saarland University, in cooperation with the molecular diagnostics company Curetis, are developing techniques to uncover these dangerous resistances a lot faster.
Company News: BioNTech to present interim PhaseI/II data for investigational mRNA vaccine in melanoma patients at AACR Annual Meeting 2017
– First Clinically Applicable, Systemic RNA-based Cancer Vaccine –
BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it will present interim data from an ongoing Phase I/II clinical trial of its Lipo-MERIT vaccine in patients with malignant melanoma at the 2017 Annual Meeting of the American Association for Cancer Research (AACR), taking place April 1 – 5 in Washington, DC.
Company News: Lead Pharma Achieves Second Milestone for Development of Autoimmune Diseases Treatments in Sanofi Collaboration
— Company receives undisclosed second milestone payment
Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of autoimmune diseases and cancer, today announced that it has achieved a second milestone under its research collaboration with Sanofi, triggering an undisclosed milestone payment.